What the Fasting Insulin Test Reveals That Standard Metabolic Labs Cannot
Fasting glucose and A1c miss insulin resistance until it is advanced. Here is what fasting insulin and HOMA-IR reveal, and how to use them in clinical practice.
Insulin resistance has been present for years before fasting glucose crosses 100. Here is the test that finds it early.
Your patient’s A1c is 5.4. Her fasting glucose is 96. Her lipid panel is unremarkable. You tell her her metabolic labs look fine. She leaves the visit feeling reassured. You move on to the next patient.
Six months later she is back. Her weight is up. She is more fatigued. Her fasting glucose is now 101. You order the same panel and tell her to watch her diet. Here is what nobody ordered in either of those visits: fasting insulin. And that is the test that would have changed everything.
Why Standard Metabolic Labs Miss Insulin Resistance
Fasting glucose and A1c measure the downstream consequences of insulin resistance. They tell you what happened after insulin stopped working effectively. By the time fasting glucose crosses 100 or A1c crosses 5.7, insulin resistance has typically been present for years.
Fasting insulin measures the upstream driver. It tells you how hard the pancreas is working to maintain that normal-looking glucose. A fasting glucose of 96 with a fasting insulin of 22 is not a normal metabolic picture. It is a pancreas working three to four times harder than it should to keep glucose in range. That is insulin resistance, and it will not show up on a standard metabolic panel until the system is already significantly compromised.
How to Order and Interpret Fasting Insulin
Fasting insulin is a standalone lab add-on. It is not included in a standard CMP or BMP. You have to order it specifically. Draw it fasting, ideally alongside a fasting glucose so you can calculate HOMA-IR. Here is how to interpret the result in functional clinical practice:
- 2 to 5 microunits per milliliter: optimal
- 6 to 10 microunits per milliliter: early insulin resistance, worth monitoring and addressing with lifestyle
- 11 to 15 microunits per milliliter: moderate insulin resistance, warrants direct clinical intervention
- Above 15 microunits per milliliter: significant insulin resistance, active driver of metabolic dysfunction
- Above 20 microunits per milliliter: severe insulin resistance, likely present for years before this visit
Calculating HOMA-IR
Once you have fasting insulin and fasting glucose you can calculate HOMA-IR. The formula is fasting insulin multiplied by fasting glucose divided by 405. Here is how to interpret the result:
- Below 1.0: optimal insulin sensitivity
- 1.0 to 1.9: mild insulin resistance beginning
- 2.0 to 2.9: moderate insulin resistance, intervention indicated
- Above 3.0: significant insulin resistance, active metabolic driver
- Above 4.0: severe insulin resistance
A patient with a fasting glucose of 96 and a fasting insulin of 22 has a HOMA-IR of 5.2. That is not a patient with normal metabolic labs. That is a patient in the advanced stages of insulin resistance with a glucose that still looks fine on paper.
What Insulin Resistance Is Actually Driving
This matters beyond weight and blood sugar. Insulin resistance is a systemic metabolic driver that affects nearly every clinical presentation your integrative patients bring to you.
In your hormonal patients, insulin resistance drives androgen excess, disrupts the HPO axis, worsens estrogen dominance, and impairs thyroid conversion. The hormone patient who is not responding to BHRT often has unaddressed insulin resistance underneath.
In your GLP-1 patients, insulin resistance that predated the medication by years is one of the primary drivers of plateau. The medication cannot override a metabolic environment it was never designed to fix.
In your gut health patients, insulin resistance worsens intestinal permeability, drives systemic inflammation, and feeds the dysbiosis that is making the gut protocol slower to work than it should. In your brain health patients, insulin resistance impairs cerebral glucose uptake and is now recognized as a primary driver of cognitive decline. Some researchers refer to Alzheimer’s disease as type 3 diabetes for this reason.
One lab. One result. A completely different clinical picture across every system you are treating.
What to Do When the Result Is Elevated
You are not diagnosing diabetes. You are identifying a metabolic pattern early enough to change the trajectory. Address dietary carbohydrate quality and timing, not necessarily low carbohydrate but strategic carbohydrate: front-load protein, reduce refined carbohydrates and ultra-processed foods, and time carbohydrate intake around physical activity. Prescribe resistance training specifically, since skeletal muscle is the primary site of glucose disposal and building lean mass improves insulin sensitivity more reliably than cardio alone. And in moderate to severe cases, consider berberine or metformin alongside the lifestyle foundation.
Written by Dr. Sheri Erwin, DNP, APRN, FNP-C
Founder, BridgeWell Integrative Education. 30+ years in healthcare, 16+ years training nurse practitioners. Systems-based, CE-accredited, and designed for NP scope from the ground up.
This Is What BridgeWell Clinical Depth Looks Like in Every Course.
Every BridgeWell course is built on the systems-based reasoning you just read about, applied to real patients and designed for NP scope.
